A novel gene-screening approach reveals QSOX1/IL1RAP as promising biomarkers for the severity of non-alcoholic fatty liver disease

Wenfeng Ma [1,2,3,4], Jinrong Huang [2], Benqiang Cai [1,4], Mumin Shao [6,7], Xuewen Yu [6,7], Mikkel Breinholt Kjær [5,8], Minling Lv [1,4], Xin Zhong [1,4], Shaomin Xu [1,4], Bolin Zhan [1,4], Qun Li [1,4], Qi Huang [1,4], Mengqing Ma [1,4], Lei Cheng [2], Yonglun Luo [2,3]*, Henning Grønbæk [5]*, Xiaozhou Zhou [1,4]*, Lin Lin [2,3]*

Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong 518033, China.

Department of Biomedicine, Aarhus University, Aarhus, Denmark.

Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.

Department of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, China.

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.

Department of Pathology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong 518033, China.

Department of Pathology, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, China.

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

* = corresponding author

Highlights

RNA-seq data from 625 liver specimens comprising healthy controls and NAFLD

patients with increasing severity were utilized for screening NAFLD biomarkers.

•

A novel unsupervised method for clustering genes based on the similarity of gene

expression across each sample enhanced the discovery of novel effective

non-invasive NAFLD biomarkers.

•

QSOX1, IL1RAP, and especially the QSOX1/IL1RAP ratio, were found to be associated

with NAFLD severity.

•

The high sensitivity of the QSOX1/IL1RAP ratio in predicting NAFLD severity was

validated with plasma proteomics quantification (AUROC = 0.95) and ELISA (AUROC =

0.82) in two independent patient cohorts.

Abstract

Background and Aims: Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease that ranges from simple steatosis to inflammation, fibrosis, and cirrhosis. To address the unmet need for new NAFLD biomarkers, we aimed to identify candidate biomarkers using publicly available RNA sequencing (RNA-seq) and proteomics data.

Methods: A novel approach involving unsupervised gene clustering was performed using homogeneously processed and integrated RNA-seq data of 625 liver specimens to screen for NAFLD biomarkers in combination with public proteomics data from healthy controls and NAFLD patients. Additionally, we validated the results in the NAFLD and healthy cohorts using enzyme-linked immunosorbent assay (ELISA) of plasma and immunohistochemical staining (IHC) of liver samples.

Results: We generated a database (https://dreamapp.biomed.au.dk/NAFLD/) for exploring gene expression changes along NAFLD progression to facilitate the identification of genes and pathways involved in the disease's progression. Through cross-analysis of the gene and protein clusters, we identified 38 genes as potential biomarkers for NAFLD severity. Up-regulation of Quiescin sulfhydryl oxidase 1

(*QSOX1*) and down-regulation of Interleukin-1 receptor accessory protein (*IL1RAP*)

were associated with increasing NAFLD severity in RNA-seq and proteomics data.

Remarkably, the QSOX1/IL1RAP ratio in plasma demonstrated effectiveness in

diagnosing NAFLD, with an area under the receiver operating characteristic (AUROC)

of up to 0.95 as quantified by proteomics profiling and an AUROC of 0.82 with ELISA.

Conclusions: We discovered a significant association between the levels of

QSOX1/IL1RAP and NAFLD severity. Furthermore, the QSOX1/IL1RAP ratio shows

promise as a non-invasive biomarker for diagnosing NAFLD and assessing its severity.

(ChiCTR2300073940).

Lay Summary

This study aimed to find non-invasive biomarkers for non-alcoholic fatty liver disease

(NAFLD). Researchers utilized a new gene clustering method to analyze RNA-seq data

from 625 liver samples. The identified biomarkers were further validated using

plasma proteomics profiling, enzyme-linked immunosorbent assay (ELISA), and liver

immunohistochemical staining (IHC) in three separate groups of healthy controls and

NAFLD patients. The study revealed that the levels of QSOX1 were elevated while

IL1RAP levels were reduced with increasing severity of NAFLD. Notably, the ratio of

QSOX1 to IL1RAP expression in plasma showed promise as a non-invasive diagnostic

tool for assessing the severity of NAFLD, eliminating the reliance on liver biopsy.

Graphical abstract

Keywords

Non-alcoholic fatty liver disease, RNA sequencing data integration, non-invasive

biomarker, quiescin sulfhydryl oxidase 1, interleukin-1 receptor accessory protein

Introduction

Non-alcoholic fatty liver disease (NAFLD) is an acknowledged hepatic manifestation of the metabolic syndrome, with an estimated global prevalence of around 25-32% (1, 2). The severity of this liver disease ranges from Non-alcoholic Fatty Liver (NAFL) with simple steatosis to Non-alcoholic Steatohepatitis (NASH) with inflammation and fibrosis, which can progress to NASH-induced cirrhosis and increase the risk of hepatocellular carcinoma (HCC).

The gold standard for diagnosing NAFLD is still liver biopsy histologically, despite its associated side effects such as pain, bleeding, and rare mortality. The need for novel, precise, cost-effective imaging tools and non-invasive biomarkers is still unmet to address these drawbacks and reduce costs (3). Moreover, non-invasive biomarkers are highly needed for replacing repeated liver biopsies when assessing liver histology during pharmacological interventions. Existing NAFLD biomarkers primarily focus on steatosis (e.g., SteatoTest™ or the lipid accumulation product), inflammation (e.g., circulating keratin 18 fragments [CK18], soluble CD163) or fibrosis (e.g., ELF, FibroTest or Pro-C3 tests) (4-8). Despite advancements in biomarker technology, development, and evaluation, an ideal biomarker for the diagnosis, prognosis, and assessment of treatment effects in NAFLD has yet to be identified.

In recent years, advancements in technologies such as RNA sequencing (RNA-seq), single-cell analysis, and spatial transcriptomics have provided deeper insights into the molecular and cellular processes involved in NAFLD progression (9-11). Large-scale profiling efforts, combined with targeted validation approaches, have led to the discovery of potential biomarkers (12, 13). However, the majority of available RNA-seq data are derived from smaller cohorts of NAFLD patients, which limits the comprehensive understanding of NAFLD severity. We propose that integrating and analyzing these datasets with an unbiased gene-based profiling strategy will provide further insights into the molecular progression of NAFLD and the identification of

biomarkers associated with NAFLD severity. In the present study, we identified over 300 NAFLD biomarkers by integrating and analyzing RNA-seq data from 625 liver samples, including their NAFLD activity scores (NAS) and fibrosis scores, along with public proteomics data. We further validated these findings in two independent NAFLD cohorts, demonstrating the potential of the QSOX1/IL1RAP ratio as a non-invasive biomarker for diagnosing NAFLD and assessing its severity.

Materials and methods

RNA-seq Data Analysis

1. Data Collection

Genome-wide RNA-seq data of human NAFLD and associated healthy controls were collected from the NCBI GEO (https://www.ncbi.nlm.nih.gov/gds, until May 2022). Only datasets that provided detailed NAS and fibrosis scores were included for further investigation.

2. Data Normalization

The SRA-formatted data were converted into FASTQ format using 'SraToolkit' (sratoolkit.2.8.2-1-centos_linux64) (https://github.com/ncbi/sra-tools). Sequencing reads were aligned to the hg19 UCSC RNA sequences Genome Reference Consortium Human Build 37 (GRCh37) using 'bowtie2' (bowtie2-2.2.5) (https://rnnh.github.io/bioinfo-notebook/docs/bowtie2.html). Only protein-coding transcripts were considered, and Transcript Per Million (TPM) values were obtained by transforming the mapped transcript reads using 'RSEM' (rsem-1.2.12) (https://github.com/deweylab/RSEM). Then, TPM values were then subjected to Trimmed Mean of M-values (TMM) normalization across all samples using 'metaseqR' ' (metaseqR 1.12.2) (14). The data from various sources involved in this study were integrated and log1p-transformed, followed by batch correction using the 'removeBatchEffect' function in the R package 'limma' (limma 3.54.2) (https://kasperdanielhansen.github.io/genbioconductor/html/limma.html) (15).

Subsequently, the data were expanded (10^x) for further analysis (**Figure 1A**).

3. RNA-seq Data Analysis and Database Construction

After normalization and batch correction, the RNA-seq data underwent Principal

Components Analysis (PCA) and unsupervised clustering using the R package 'Seurat'

(Seurat-4.3.0) (https://satijalab.org/seurat/articles/get_started.html). We utilized the

'LogNormalize' method for global-scaling normalization, which normalized the

feature expression measurements across different samples for each gene by the total

expression. The normalized values were multiplied by a scale factor (default:

10,000) and log1p-transformed. Subsequently, scaling was applied to the identified

variable features (default: 2,000). PCA was then performed on the scaled data, with a

default setting of computing and storing 50 Principal Components (PCs). To cluster

the genes, we employed modularity optimization techniques using a graph-based

clustering approach. The dimensions of reduction were set to 1:20, and

the resolution parameter was set to 2.3 (16).

To show the gene expression variation during the development of NAFLD associated

with both NAS and fibrosis scores, we generated an RNA-seq database using

'ShinyCell' (https://github.com/SGDDNB/ShinyCell). This database was deployed at

https://dreamapp.biomed.au.dk/NAFLD/.

Proteomics Data Collection and Analysis

The proteomics cohort dataset (PXD011839) includes 10 healthy controls, 10 NAFLD

patients with normal glucose tolerance (NAFLD_ngt), 10 NAFLD patients with type 2

diabetes (NAFLD_T2D), and 10 NAFLD patients with cirrhosis (17). We performed the

statistical analysis using R-4.3.0 on the dataset (EV1, tab4)

(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396370/bin/MSB-15-e8793-s003.

xlsx). The NAFLD_ngt and NAFLD_T2D groups were merged into a single NAFLD group,

resulting in three groups: healthy controls, NAFLD, and cirrhosis.

Similar to RNA-seq analysis, we used 'Seurat' (Seurat-4.3.0) and employed the

'LogNormalize' method for global-scaling normalization. This method normalized the

feature expression measurements across different samples for each protein by the

total expression. The normalized values were multiplied by a scale factor (default:

10,000) and log1p-transformed. Subsequently, scaling was applied to the identified

variable features (default: 2,000). PCA was performed on the scaled data, with a total

of 39 Principal Components (PCs) computed and stored. Additionally, we calculated

the log fold-change of the average expression between two groups (avg_log2FC) by

comparing the health and NAFLD groups, as well as the NAFLD and cirrhosis groups.

By setting avg_log2FC > 0, we selected up- and down-regulated proteins associated

with increasing severity of NAFLD.

Validation of QSOX1 and IL1RAP as Biomarkers in NAFLD

1. Study Design

Our objective was to investigate whether *QSOX1* and *IL1RAP* gene expression levels,

as well as their encoded proteins, could predict the histological severity of NAFLD. To

address this issue, we investigated the plasma concentrations of QSOX1 and IL1RAP

in the proteomics data of healthy and NAFLD cohorts. Additionally, we conducted

enzyme-linked immunosorbent assay (ELISA) tests for plasma QSOX1/IL1RAP in a

cohort comprising healthy subjects and NAFLD patients recruited at Shenzhen

Traditional Chinese Medicine Hospital, China (SZTCMH).

2. Human Samples

A total of 28 ultrasound-proven adult NAFLD patients, including NAFLD_ngt and

NAFLD_T2D, and 14 healthy controls were enrolled from SZTCMH. Other diagnoses

and etiologies, such as excessive alcohol consumption, viral hepatitis, autoimmune

liver disease, and the use of steatogenic compounds, were excluded. Archived

plasma samples were collected between October and December 2022. Healthy

subjects and NAFLD patients were given informed consent according to the approved

clinical protocols of the Ethical Committee of SZTCMH. Clinical information, including

body mass index (BMI) and standard biochemistry (liver, kidney, hematology) with metabolic profiling (glucose, insulin, lipids), was collected. Fibroscan with controlled attenuation parameter (CAP) values was performed to assess fibrosis and steatosis. Clinical information for the healthy controls and NAFLD patients can be found in **Supplementary Table 4**.

For immunohistochemical staining (IHC), 12 fixed liver tissues were collected from archived histological samples at SZTCMH between 2014 and 2023. These samples were scored based on the NAS score (N0 to N8) and fibrosis score (F0 to F4) by two pathologists (MMS and XWY). Six samples were from mild NAFLD patients (N0-4, F0-2), and six were from severe NAFLD patients (N5-8, F3-4). The clinical study was approved by the Ethical Committee of SZTCMH, and the approved clinical protocols adhere to the Helsinki Declaration (No. K2022-174-01).

3. ELISA

Blind ELISA tests were conducted on the collected plasma samples. Randomly assigned sample identifiers and positions were used to ensure blindness to the clinical information and NAFLD stages. The levels of QSOX1 and IL1RAP were measured using QSOX1 ELISA Kits (Catalog No. YJ145587, Lot No. 12/2022 from Enzyme-linked Biotechnology, Shanghai, China) and IL1RAP ELISA Kits (Catalog No. YJ130558, Lot No. 12/2022 from Enzyme-linked Biotechnology, Shanghai, China), respectively. The measurements followed the manufacturer's instructions, and the absorbance values were measured at 450nm. In order to ensure the reliability of the ELISA Kits, a pre-experiment was conducted three times before the formal experiment.

4. IHC

We examined the association of QSOX1 and IL1RAP with human NAFLD severity by performing IHC on formalin-fixed and paraffin-embedded liver sections from 6 mild NAFLD patients and 6 severe NAFLD patients. The 3 μm-thick paraffin sections were

deparaffinized and rehydrated with distilled water. Antigen retrieval was carried out using pH 9.0 EDTA buffer, followed by 20 minutes of boiling and washing with 1X PBS. Subsequently, the slides were blocked with 1% bovine serum albumin in 1X PBS for 15 minutes and then incubated overnight at 4℃ with QSOX1 (Rabbit anti-human, Catalog No. Ab235444, Lot No. GR3386311-2 from Abcam) or IL1RAP (Rabbit anti-human, Catalog No.35605, Lot No. 4926 from Sabbiotech) antibodies at a concentration of 20 μg/ml. The following day, the slides were washed with 1X PBS and incubated with Goat anti-rabbit IgG H&L (Catalog No. Ab205718, Lot No. ab205718 from Abcam) for 15 minutes at room temperature, followed by another wash with 1X PBS. The images were captured with a light microscope and 3DHISTECH digital scanner (https://www.3dhistech.com/).

The IHC results were analyzed using the software tool 'ImagineJ (Fiji)'. To prevent potential bias, we randomly selected five locations of the same size from each sample at 20x magnification using 3DHISTECH CaseViewer_2.4 (https://www.3dhistech.com/solutions/caseviewer/). Using 'ImagineJ', we applied the 'Colour Deconvolution' tool with vectors=[H DAB], followed by selecting the Colour_2 pictures and running '8-bit'. Standard thresholds were used (QSOX1: setThreshold (60, 230), IL1RAP: setThreshold (94, 214)) (18, 19). The average integrated density from the five sites was calculated and used as the integrated density value for each sample, which was then subjected to statistical analysis.

5. Statistical analysis

The significance for all statistical tests was two-sided, with P < 0.05. All data analysis was presented in the plots using R-4.3.0, and MedCalc was used to calculate the AUROC, sensitivity, specificity, optimal cutoff value, and sample size.

Results

Overview of RNA-seq data and NAFLD patient cohorts

After applying stringent filtering criteria based on the availability of histological NAS and fibrosis scores, five datasets (including GSE115193, GSE134422, GSE135448, GSE160016, and GSE164441) were excluded from the analysis, while seven datasets (GSE105127, GSE107650, GSE126848, GSE130970, GSE135251, GSE162694, and GSE167523) were included. These datasets collectively comprise 81 healthy controls (N0F0) and 544 NAFLD patients. The severity of NAFLD patients was classified based on the NAS score (ranging from N1 to N8) and the fibrosis score (ranging from F0 to F4) using the scoring systems proposed by Brunt (20) and Kleiner (21), respectively (**Table 1**). A positive correlation was observed between NAS and fibrosis scores (Pearson R = 0.64, P = 4.94E-74, **Table 1**), indicating an association with NAFLD severity.

Normalization and Integration of RNA-seq Data

To address the issue of batch effects resulting from differences in sequencing technology and studies, we processed the integrated data as depicted in **Figure 1A**. Genes with low expression were filtered out, resulting in a total of 17,946 protein-coding genes. Principal component analysis (PCA) demonstrated that normalization effectively eliminated noticeable batch effects (**Figure 1B**). Moreover, neither the NAS nor fibrosis scores appeared to be the main factors contributing to sample separation (**Figure 1D, E**). Instead, the normalized RNA abundance (nCount) in each sample emerged as the key component influencing transcriptome profiles (**Figure 1C**).

Unsupervised Gene Clustering Identifies Clusters of Genes Associated with NAFLD Severity.

To identify genes associated with NAFLD severity, we utilized a previously developed unsupervised gene clustering method based on the similarity of gene expression

patterns across each sample (22). By setting a resolution of 2.3, we identified a total

of 38 gene clusters (**Supplementary Figure S1**). Notably, cluster 4, consisting of 1021

genes, consistently exhibited increased expression with higher NAS and fibrosis

scores (**Figure 2A, Supplementary Figure S2A**). Conversely, cluster 14, comprising

643 genes, showed decreased expression with increasing NAS and fibrosis scores

(**Figure 2B**, **Supplementary Figure S2B**).

To unveil the biological functions of these gene clusters, we performed Gene

Ontology (GO) analysis using the R package 'ClusterProfiler' (ClusterProfiler-4.8.0).

Specifically, we focused on cluster 4, which consisted of up-regulated genes. The GO

analysis revealed significant enrichment of genes involved in the fibrosis-related

process, such as extracellular matrix (ECM) organization (p.adjust = 9.77E-34),

extracellular structure organization (p.adjust = 9.77E-34), external encapsulating

structure organization (p.adjust = 1.09E-33), and cell-substrate adhesion (p.adjust =

3.35E-17). Notably, the expression of multiple genes involved in the ECM processes,

such as *COL5A3, FBLN5, SPINT2, COL1A1, COL1A2, COL3A1, COL4A1, COL4A4,*

COL12A1, COL15A1, and *COL16A1*, showed a gradual up-regulation during the

progression of NAFLD (**Figure 2A, Supplementary Figure S3**).

In contrast, cluster 14, which displayed a reverse correlation with NAS and fibrosis

scores, was significantly enriched in metabolic processes, indicating an association

between NAFLD progression and attenuated liver metabolism. The down-regulated

genes in this cluster were particularly enriched in processes such as organic acid

catabolic process (p.adjust = 2.57E-22), carboxylic acid catabolic process (p.adjust =

2.57E-22), small molecule catabolic process (p.adjust = 5.28E-22), alpha-amino acid

metabolic process (p.adjust = 6.03E-20), fatty acid metabolic process (p.adjust =

2.60E-10), and alcohol metabolic process (p.adjust = 1.35E-09). Notably, genes

encoding enzymes of the Cytochrome P450 superfamily, including *CYP1A2, CYP2C19,*

CYP2J2, CYP2E1, CYP4A11, CYP4A22, CYP4F11, CYP2C8, and *CYP3A4*, were

down-regulated with increasing NAFLD severity (**Figure 2B**, **Supplementary Figure**

S4). For a comprehensive list of all enriched GO terms for genes in cluster 4 and 14,
please refer to **Supplementary Table 1**.

In addition, we developed a NAFLD gene expression database (NAFLD-DB) to
facilitate the exploration and comparison of all identified protein-coding genes based
on NAFLD severity. The NAFLD-DB (https://dreamapp.biomed.au.dk/NAFLD/) was
constructed using the ShinyCell framework (23), which was specifically designed for
convenient exploration and sharing of single-cell transcriptome data.

Identification of Candidate Diagnostic Biomarkers.
We employed an additional complementary strategy to further refine our list of
candidate genes. In this approach, we first analyzed the plasma protein levels from a
NAFLD cohort in a proteomics dataset (PXD011839) (17). We selected proteins that
showed positive correlations with increasing NAFLD severity (avg_log2FC > 0) and
proteins that showed negative correlations. As a result, we identified 148
up-regulated proteins and 114 down-regulated proteins associated with increasing
NAFLD severity (**Figure 2C, D**).

The secretome, which consists of secreted proteins, has emerged as a valuable
resource for disease diagnostics (24-26). In our study, we aim to identify potential
diagnostic markers among the candidate genes by comparing our gene clusters with
the secretome database from the Human Protein Atlas (27). This cross-analysis
revealed a total of 349 genes encoding secreted proteins, with 249 genes showing
up-regulation and 100 genes showing down-regulation (**Figure 2E**). Notably, our
approach successfully identified a comprehensive list of previously known NAFLD
diagnostic and prognostic markers, including *ADAMTSL2* (28), *AEBP1* (29), and *BGN*
(30) (**Supplementary Table 2**), further validating the effectiveness of our approach.

Next, we intersected the protein-encoding genes of these proteins with the
secretome genes and the candidate genes generated from our RNA-seq analysis.

Through this cross-comparison, we identified 16 up-regulated secreting genes (*A2M,*

C7, COL6A3, COLEC11, ENPP2, FBLN1, FBN1, FCGBP, IGFBP6, LCN2, LUM, MMP2,

PAPLN, PTGDS, **QSOX1**, *VWF*) and 22 down-regulated secreting genes (*AZGP1, C1RL,*

C4BPA, C6, C8B, CFHR3, CNDP1, F2, GC, HP, HPR, **IL1RAP**, *ITIH1, ITIH2, ITIH4, KLKB1,*

PON3, SERPINA10, SERPINC1, SERPING1, SMPDL3A, TTR) associated with increasing

NAFLD severity in both the RNA-seq and proteomics data (**Supplementary Figure S5**).

QSOX1 and IL1RAP are promising biomarkers for NAFLD severity

To demonstrate the applicability of our NAFLD-DB and validate the association of

differential gene expression with increasing NAFLD severity, we selected two

representative genes, *QSOX1* and *IL1RAP,* which showed positive and negative

correlations with increasing NAFLD severity**.** We examined their expression levels in

comparison to patients with a NAS or fibrosis score of 0 (N0 or F0). The expression of

QSOX1 was significantly correlated with the severity of NAFLD compared to N0 or F0

patients: N1-4 (p = 0.003), N5-8 (p = 1.9E-10), F1-2 (p = 0.001), F3-4 (p = 6.5E-8)

(**Figure 3A, B**). On the other hand, *IL1RAP* expression was significantly lower in

patients with increased NAFLD severity compared to N0 or F0: N1-4 (p = 1E-5), N5-8

(p = 4.7E-10), F1-2 (p = 0.00012), F3-4 (p = 0.00013) (**Figure 3C, D**).

Since *QSOX1* and *IL1RAP* exhibited opposite correlations with NAFLD severity, we

further explored whether the ratio of QSOX1/IL1RAP could better distinguish

between patient groups. Our results showed that compared to N0 or F0 patients, the

ratio of QSOX1 to IL1RAP mRNA levels showed even greater separation: N1-4 (p =

7.6E-8), N5-8 (5.9E-16), F1-2 (4.6E-6), F3-4 (6.8E-8) (**Figure 3E, F**). These findings

suggest that the QSOX1/IL1RAP ratio has the potential as a biomarker for diagnosing

NAFLD severity.

Validation of Plasma QSOX1/IL1RAP Levels as Biomarkers for NAFLD Severity with

NAFLD Proteomics Cohort

To further validate the potential of QSOX1 and IL1RAP as biomarkers for NAFLD

severity, we analyzed the plasma levels of QSOX1 and IL1RAP in a NAFLD proteomics

cohort (PXD011839) previously conducted by Niu L. and colleagues. This cohort

consisted of 10 healthy controls and 30 patients with NAFLD or NAFLD-induced

cirrhosis (17).

Consistent with our liver RNA profiling results in livers, the analysis of plasma

proteomics data from this independent NAFLD cohort showed a significant increase

in plasma QSOX1 levels in patients with NAFLD (Wilcoxon rank sum test, p = 0.021)

and cirrhosis (p = 0.049) compared to healthy controls (**Figure 4A**). Conversely,

IL1RAP levels were significantly reduced in patients with NAFLD (p = 5.8E-5) and

cirrhosis (p = 0.0011) (**Figure 4B**). Moreover, when considering the combined marker

of plasma QSOX1/IL1RAP ratio, it demonstrated even greater significance in

distinguishing NAFLD (p = 9.3E-6) and cirrhosis (p = 0.00013) patients from the

control group, compared to using QSOX1 or IL1RAP alone (**Figure 4C**).

To access the diagnostic sensitivity and specificity of QSOX1, IL1RAP, and their ratio

for NAFLD severity, we conducted ROC curve analysis using the 'MedCalc' tool (30).

The sample sizes for each comparison were evaluated and are listed in

Supplementary Table 3. The AUROC of the QSOX1/IL1RAP ratio for distinguishing

NAFLD patients from healthy controls was 0.95, with a cutoff value of 1.12. The

sensitivity was determined to be 90%, and the specificity was 100%. Notably, the

efficacy of the QSOX1/IL1RAP ratio was superior to that of IL1RAP alone

(AUROC=0.92) or QSOX1 alone (not significant). Similarly, when assessing the

differentiation between cirrhosis patients and healthy controls, the AUROC of the

QSOX1/IL1RAP ratio was 0.96, with a cutoff value of 1.12. The sensitivity was 90%,

and the specificity was 100%.

These results indicate that the QSOX1/IL1RAP ratio holds promise as a highly

effective biomarker for diagnosing NAFLD severity, surpassing the individual

biomarkers alone, and maintaining better sensitivity and specificity in distinguishing

NAFLD patients and cirrhosis patients from healthy individuals.

Validation of QSOX1 and IL1RAP as biomarkers for NAFLD in another patient cohort

To further validate the utility of QSOX1 and IL1RAP as biomarkers for NAFLD, we

conducted a validation study in healthy controls and NAFLD patients recruited from

the Department of Liver Disease of Shenzhen Traditional Chinese Medicine Hospital.

Plasma samples were collected from 14 healthy subjects and 28 newly diagnosed

NAFLD patients. Clinical information for the healthy controls and NAFLD patients can

be found in **Supplementary Table 4**.

We measured plasma levels of QSOX1 and IL1RAP using an enzyme-linked

immunosorbent assay (ELISA). Consistent with our previous findings, plasma levels of

QSOX1 (Wilcoxon rank sum test, p = 0.043), IL1RAP (p = 0.035), and the

QSOX1/IL1RAP ratio (p = 0.00061) were significantly different between NAFLD

patients and controls (**Figure 4D, E, F**).

To assess the diagnostic value of QSOX1 and IL1RAP as non-invasive biomarkers for

NAFLD by ELISA, we calculated the AUROC of the QSOX1/IL1RAP ratio in the ELISA

test to distinguish NAFLD patients from healthy controls. The QSOX1/IL1RAP ratio

exhibited an AUROC of 0.82. With a cutoff of 0.05, the sensitivity was 93%, and the

specificity was 57%. In comparison, the AUROC of QSOX1/IL1RAP ratio quantified by

ELISA showed less efficacy in distinguishing NAFLD patients from healthy controls

(**Supplementary Table 3**), which may be attributed to the sensitivity of protein

quantification methods and small sample size.

To further validate the association between QSOX1 and IL1RAP protein levels and

NAFLD severity, we assessed their levels in liver biopsies from mild and severe NAFLD

patients using IHC. Our results consistently demonstrated a significant correlation

between QSOX1 and IL1RAP levels and NAFLD severity (**Figure 5A**). Quantification of

QSOX1 and IL1RAP levels based on IHC confirmed that the QSOX1/IL1RAP ratio (p =

0.027) could distinguish the severe NAFLD group (n=6; NAS 5-8, fibrosis score 3-4)

from the mild NAFLD group (n=6; NAS 0-4, Fibrosis score 0-2) (**Figure 5B, C**).

Collectively, these findings suggest that the QSOX1/IL1RAP ratio holds promise as an

effective biomarker for the early diagnosis and prediction of NAFLD severity.

Discussion

This study is the first to integrate publicly available RNA-seq datasets from over 600 NAFLD patients with varying stages of disease severity, combined with proteomics data analysis of publicly available datasets. The key findings suggest that the QSOX1 and IL1RAP, particularly the QSOX1/IL1RAP ratio hold promise as potential biomarkers for NAFLD severity assessment. These results align with recent research highlighting the importance of different transcriptional profiles specific to NAS and fibrosis scores, offering valuable insights into the molecular mechanisms driving disease progression from simple steatosis to inflammation and fibrosis (31, 32).

The Advantages of Utilizing Integrated RNA-seq Data for Investigating NAFLD Biomarkers

Despite the growing availability of RNA-seq data in this field, many original studies have been limited by small sample sizes and biased sample distribution, making it challenging to accurately decipher transcriptional differences across various stages of NAFLD(31-35). Several studies have attempted to identify diagnostic biomarkers and potential drug targets. For instance, Brosch et al. conducted a positional analysis of transcriptomes across three micro-dissected liver zones from 19 NAFLD patients (33). Suppli et al. demonstrated that immunohistochemical markers offer greater objectivity in distinguishing hepatocyte injury between NASH and NAFL (34). In the pursuit of diagnostic genes and novel drug targets, Hoang et al. studied 6 histologically normal and 72 NAFLD patients, while Pantano et al. studied 31 histologically normal and 112 NAFLD patients. These studies revealed that specific cells proportion and candidate gene signatures can accurately predict fibrosis stage and disease progression (31, 32). Likewise, Govaere et al. observed the correlation between gene expression and histology in a cohort of 10 controls and 206 NAFLD patients (35). In contrast to the studies above that identified sets of potential biomarker genes, Kozumi et al. validated thrombospondin 2 (THBS2) as a non-invasive biomarker for NAFLD. They confirmed its potential in identifying the

disease stages among 98 NAFLD patients, and the serum levels of its encoded protein

TSP-2, measured by ELISA, showed an AUROC of 0.78 in the diagnosing of NASH

among 213 patients with biopsy-proven NAFLD (36). The major challenge of

combining and analyzing these diverse datasets lies in achieving homogeneous

processing, which requires substantial time and computational resources (37, 38). To

generate more robust and compelling results, we employed unbiased integration of

comprehensive NAFLD data to profile the liver transcriptome across a broad

spectrum of NAFLD severity in our study, incorporating all the aforementioned

samples.

The Superiority of QSOX1 and IL1RAP as Potential Biomarkers of NAFLD

The high prevalence and associated risks of NAFLD have driven global efforts to

identify improved diagnostic biomarkers. However, most existing biomarkers are

primarily suited for evaluating fibrosis (3, 39-41). The Fibrosis-4 (FIB-4) test,

commonly used in clinical practice, is sub-optimal for screening purposes, as it carries

the risks of both overdiagnosis and false negatives, particularly in patients at risk of

chronic liver disease (8). Although the patented ELF™ test was highly recommended

for ruling out advanced fibrosis, it comes with higher costs. Several steatosis scores,

such as the SteatoTest™ and the fatty liver index (FLI), have been proposed for

steatosis detection, but they do not provide substantial additional information

beyond routine clinical, laboratory, and imaging examinations conducted in

patients suspected of having NAFLD(8). Non-coding RNAs (ncRNAs), which exhibit

aberrant expression associated with NAFLD, have emerged as potential biomarkers

for NAFLD pathology, and circulating ncRNAs, including miR-122 and lncRNAs are

proposed as potential biomarkers for NAFLD severity and progression (42-48).

Despite the development of new biomarkers, there is still uncertainty surrounding

their predictive value, underscoring the urgent need to develop novel, cost-effective,

and efficient biomarkers with high sensitivity and specificity for NAFLD prediction

and monitoring (4, 49).

Previous studies have explored the relationship between QSOX1, IL1RAP, and NAFLD

or steatosis(12, 50). QSOX1 has been suggested as a potential diagnostic biomarker

for NAFLD, playing a significant role in lipid metabolism as an enzyme expressed in

various tissues, particularly in quiescent fibroblasts (33, 51, 52). IL1RAP is localized in

vesicles and cytosol, and it is secreted into the bloodstream. Notably, IL1RAP

expression at the RNA level was specifically detected in the liver and hepatocytes

(27). Hence, the combination of QSOX1 and IL1RAP as secretome genes and proteins

was selected as a potential biomarker combination.

The potential of QSOX1, IL1RAP, and their ratio as biomarkers for NAFLD was

demonstrated through the analysis of public RNA-seq and proteomics data, ELISA

tests conducted on patients' plasma, and IHC performed on fixed liver slides. These

findings suggest that QSOX1, IL1RAP, and their ratio hold promise as effective

biomarkers for NAFLD. Notably, the higher AUROC values for NAFLD diagnosis

achieved by QSOX1, IL1RAP, and their ratio highlight their efficacy as NAFLD

biomarkers.

Limitation and Future Prospects.

The current study possesses several strengths, including the integration and

processing of RNA-seq data from over 600 NAFLD patients with varying degrees of

NAFLD severity, as well as validation using proteomics data and samples from NAFLD

patients and controls. Furthermore, the well-established database with a

user-friendly interface could benefit the research community in exploring

differentially expressed genes in NAFLD at various stages. However, there are also

limitations to consider. For instance, some samples in the GSE126848 and GSE167523

datasets lacked individual NAS and fibrosis scores. To address this issue,

we standardized scores based on their categories in the original articles, and the

impact on the results was deemed negligible due to the provision of general stages

and unsupervised gene clustering. Machine learning, an essential tool for biomarker

validation and sample classification validation, should be employed to train large

cohorts of biopsy-proven NAFLD patients and healthy controls. However, this would

require an extended recruiting period(53) to determine the sensitivity and specificity

of the QSOX1/IL1RAP ratio for NAFLD diagnosis and staging.

Although newer technologies such as single-cell RNA sequencing (scRNA-seq) and

spatial sequencing have gained popularity, RNA-seq still serves as a valuable tool in

uncovering the pathogenesis of NAFLD (13). Computational analysis limitations make

it impractical for large cohort research, and single-cell suspension processing may

affect cell abundance and cell type representation, particularly in hepatic ballooning

cells in NAFLD (54). Single-nuclei RNA sequencing (snRNA-seq) captures cell

frequency more accurately than scRNA-seq but captures lower gene expression.

Spatial transcriptomics and proteomics have limitations for discovering invasive

biomarkers of NAFLD as they focus on small sampling areas (11). The combination of

all these biological tools holds potential for future research.

In conclusion, through a novel approach of unsupervised gene clustering performed

on integrated RNA-seq data, we have discovered a significant association between

QSOX1 and IL1RAP levels and NAFLD severity, with their ratio showing potential as a

non-invasive biomarker for diagnosing and assessing the severity of NAFLD.

Validation of our plasma-level findings in larger cohorts of liver biopsies is required,

but it holds promise as a new tool to diagnose NAFLD severity and reduce the need

for liver biopsies. Our approach may lead to the discovery of more NAFLD biomarkers,

and the ratios of other up-regulated and down-regulated genes associated with

increasing NAFLD severity also have the potential to be verified as potential

biomarkers.

Abbreviations

AUROC, area under the receiver operating characteristic; avg_log2FC, log fold-change

of the average expression between the two groups; BMI, body mass index; CK18,

circulating keratin 18 fragments; ECM, extracellular matrix; ELISA, enzyme-linked

immunosorbent assay; F, Fibrosis score; FIB-4, Fibrosis-4; GEO, Gene Expression

Omnibus; GO, Gene Ontology; GRCh37, Genome Reference Consortium Human Build

37; HCC, hepatocellular carcinoma; IHC, immunohistochemistry staining; IL1RAP,

Interleukin-1 receptor accessory protein; lg, log10; PCA, Principal components

analysis; QSOX1, Quiescin sulfhydryl oxidase 1; RNA-seq, RNA sequencing; N, NAS

score; NAFL, Non-alcoholic Fatty Liver; NAFLD, Non-alcoholic fatty liver disease;

NAFLD-DB, NAFLD gene expression database; NAFLD_ngt, NAFLD with normal

glucose tolerance; NAFLD_T2D, NAFLD with type 2 diabetes; NAS, NAFLD activity

scores; NASH, Non-alcoholic Steatohepatitis; ncRNAs, non-coding RNAs; scRNA-seq,

single-cell RNA sequencing; snRNA-seq, Single-nuclei RNA sequencing; SZTCMH,

Shenzhen Traditional Chinese Medicine Hospital, China; THBS2, thrombospondin 2;

TMM, Trimmed Mean of M-values; TPM, Transcript Per Million.

Financial support

This research was funded by the Shenzhen Science and Technology Project and

Sanming Project of Medicine in Shenzhen, China (grant nos. SZSM201612074,

JCYJ20180302173542393 and JCYJ20170817094901026).

Authors' contributions

YLL, HG, WFM and LL designed the study and interpreted the data. The analysis

strategy has been developed by LL and WFM. WFM, JRH, BQC, MLL, XZ, SMX and

MBK collected and assembled the data. WFM drafted the manuscript. WFM, JRH and

LC performed data analysis and/or interpretation. Technical support: YLL, LL, JRH, ZXZ,

MMS and XWY. Study participant inclusion: ZXZ, WFM, BQC, MLL, XZ, SMX, BLZ, QL,

QH, MQM. All authors reviewed and approved the final version of the manuscript.

Data and code availability statement

589 The data that support the findings of this study are available from the corresponding

590   author upon reasonable request.

Conflict of interest

593   Henning Grønbæk has received research grants from Abbvie, Intercept, ARLA Food

594   for Health, ADS AIPHIA Development Services AG. Consulting Fees from Ipsen, NOVO,

595   Pfizer. Lecturer for AstraZeneca and EISAI; and on Data Monitoring Committee at

596   CAMURUS AB. All other authors have no conflicts of interest to declare.

Reference

1.   Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, et al.
Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol
Hepatol 2022;19:60-78.

2.   Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, et al. The prevalence
and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol
Hepatol 2022;7:851-861.

3.   Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules 2022;12.

4.   Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical
prediction rules and blood-based biomarkers. J Hepatol 2018;68:305-315.

5.   Kazankov K, Barrera F, Moller HJ, Rosso C, Bugianesi E, David E, Younes R, et al. The macrophage
activation marker sCD163 is associated with morphological disease stages in patients with
non-alcoholic fatty liver disease. Liver Int 2016;36:1549-1557.

6.   Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past,
present and future. J Hepatol 2022;76:1362-1378.

7.   Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells 2020;9.

8.   European Association for the Study of the Liver. Electronic address eee, Clinical Practice
Guideline P, Chair, representative EGB, Panel m. EASL Clinical Practice Guidelines on non-invasive tests
for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-689.

9.   Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD - more than
inflammation. Nat Rev Endocrinol 2022;18:461-472.

10.   Wang ZY, Keogh A, Waldt A, Cuttat R, Neri M, Zhu S, Schuierer S, et al. Single-cell and bulk
transcriptomics of the liver reveals potential targets of NASH with fibrosis. Sci Rep 2021;11:19396.

11.   Guilliams M, Bonnardel J, Haest B, Vanderborght B, Wagner C, Remmerie A, Bujko A, et al. Spatial
proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell
2022;185:379-396 e338.

12.   Green CD, Dozmorov MG, Spiegel S. Analysis of Liver Responses to Non-alcoholic Steatohepatitis
by mRNA-Sequencing. Methods Mol Biol 2022;2455:163-179.

13.   Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet
2019;20:631-656.

14. van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling,
and transformations: improving the biological information content of metabolomics data. BMC
Genomics 2006;7:142.

15. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential
expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.

16. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, Lee MJ, et al. Integrated
analysis of multimodal single-cell data. Cell 2021;184:3573-3587 e3529.

17. Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, et al. Plasma
proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst
Biol 2019;15:e8793.

18. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat
Methods 2012;9:671-675.

19. Shu J, Dolman GE, Duan J, Qiu G, Ilyas M. Statistical colour models: an automated digital image
analysis method for quantification of histological biomarkers. Biomed Eng Online 2016;15:46.

20. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic
steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol
1999;94:2467-2474.

21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design
and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology
2005;41:1313-1321.

22. Karlsson M, Sjostedt E, Oksvold P, Sivertsson A, Huang J, Alvez MB, Arif M, et al. Genome-wide
annotation of protein-coding genes in pig. BMC Biol 2022;20:25.

23. Ouyang JF, Kamaraj US, Cao EY, Rackham OJL. ShinyCell: Simple and sharable visualisation of
single-cell gene expression data. Bioinformatics 2021.

24. Liu Y, Ciotti GE, Eisinger-Mathason TSK. Hypoxia and the Tumor Secretome. Adv Exp Med Biol
2019;1136:57-69.

25. Crescenzi E, Leonardi A, Pacifico F. NGAL as a Potential Target in Tumor Microenvironment. Int J
Mol Sci 2021;22.

26. Zhou X, Zhang J, Lv W, Zhao C, Xia Y, Wu Y, Zhang Q. The pleiotropic roles of adipocyte secretome
in remodeling breast cancer. J Exp Clin Cancer Res 2022;41:203.

27. Uhlen M, Karlsson MJ, Hober A, Svensson AS, Scheffel J, Kotol D, Zhong W, et al. The human
secretome. Sci Signal 2019;12.

28. Corey KE, Pitts R, Lai M, Loureiro J, Masia R, Osganian SA, Gustafson JL, et al. ADAMTSL2 protein
and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults
with NAFLD. J Hepatol 2022;76:25-33.

29. Gerhard GS, Hanson A, Wilhelmsen D, Piras IS, Still CD, Chu X, Petrick AT, et al. AEBP1 expression
increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p.
PLoS One 2019;14:e0219764.

30. Cengiz M, Yilmaz G, Ozenirler S. Serum Biglycan as a Diagnostic Marker for Non-Alcoholic
Steatohepatitis and Liver Fibrosis. Clin Lab 2021;67.

31. Hoang SA, Oseini A, Feaver RE, Cole BK, Asgharpour A, Vincent R, Siddiqui M, et al. Gene
Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty
Liver Disease. Sci Rep 2019;9:12541.

32. Pantano L, Agyapong G, Shen Y, Zhuo Z, Fernandez-Albert F, Rust W, Knebel D, et al. Molecular

characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci Rep 2021;11:18045.

33. Brosch M, Kattler K, Herrmann A, von Schonfels W, Nordstrom K, Seehofer D, Damm G, et al.

Epigenomic map of human liver reveals principles of zonated morphogenic and metabolic control. Nat

Commun 2018;9:4150.

34. Suppli MP, Rigbolt KTG, Veidal SS, Heeboll S, Eriksen PL, Demant M, Bagger JI, et al. Hepatic

transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared

with healthy normal-weight individuals. Am J Physiol Gastrointest Liver Physiol 2019;316:G462-G472.

35. Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, et al. Transcriptomic

profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for

steatohepatitis and fibrosis. Sci Transl Med 2020;12.

36. Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, Motooka D, et al. Transcriptomics

Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology

2021;74:2452-2466.

37. Stupnikov A, McInerney CE, Savage KI, McIntosh SA, Emmert-Streib F, Kennedy R, Salto-Tellez M,

et al. Robustness of differential gene expression analysis of RNA-seq. Comput Struct Biotechnol J

2021;19:3470-3481.

38. Shakola F, Palejev D, Ivanov I. A Framework for Comparison and Assessment of Synthetic

RNA-Seq Data. Genes (Basel) 2022;13.

39. Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis by

elastography in NAFLD. Nat Rev Gastroenterol Hepatol 2018;15:274-282.

40. Masoodi M, Gastaldelli A, Hyotylainen T, Arretxe E, Alonso C, Gaggini M, Brosnan J, et al.

Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev

Gastroenterol Hepatol 2021;18:835-856.

41. Wong VW, Adams LA, de Ledinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD

and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461-478.

42. Panera N, Gnani D, Crudele A, Ceccarelli S, Nobili V, Alisi A. MicroRNAs as controlled systems and

controllers in non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:15079-15086.

43. Fang Z, Dou G, Wang L. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Int J

Biol Sci 2021;17:1851-1863.

44. Qian X, Zong W, Ma L, Yang Z, Chen W, Yan J, Xu J. MM-associated circular RNA downregulates

microRNA-19a through methylation to suppress proliferation of pancreatic adenocarcinoma cells.

Bioengineered 2022;13:9294-9300.

45. Jampoka K, Muangpaisarn P, Khongnomnan K, Treeprasertsuk S, Tangkijvanich P, Payungporn S.

Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD).

Microrna 2018;7:215-222.

46. Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, et al. Analysis of

association between circulating miR-122 and histopathological features of nonalcoholic fatty liver

disease in patients free of hepatocellular carcinoma. BMC Gastroenterol 2016;16:141.

47. Wang W, Min L, Qiu X, Wu X, Liu C, Ma J, Zhang D, et al. Biological Function of Long Non-coding

RNA (LncRNA) Xist. Front Cell Dev Biol 2021;9:645647.

48. Atanasovska B, Rensen SS, Marsman G, Shiri-Sverdlov R, Withoff S, Kuipers F, Wijmenga C, et al.

Long Non-Coding RNAs Involved in Progression of Non-Alcoholic Fatty Liver Disease to Steatohepatitis.

Cells 2021;10.

49. Chee D, Ng CH, Chan KE, Huang DQ, Teng M, Muthiah M. The Past, Present, and Future of
Noninvasive Test in Chronic Liver Diseases. Med Clin North Am 2023;107:397-421.

50. Bozaoglu K, Attard C, Kulkarni H, Cummings N, Diego VP, Carless MA, Shields KA, et al. Plasma
levels of soluble interleukin 1 receptor accessory protein are reduced in obesity. J Clin Endocrinol
Metab 2014;99:3435-3443.

51. Gao R, Wang J, He X, Wang T, Zhou L, Ren Z, Yang J, et al. Comprehensive analysis of endoplasmic
reticulum-related and secretome gene expression profiles in the progression of non-alcoholic fatty
liver disease. Front Endocrinol (Lausanne) 2022;13:967016.

52. Reznik N, Fass D. Disulfide bond formation and redox regulation in the Golgi apparatus. FEBS Lett
2022;596:2859-2872.

53. Ledesma D, Symes S, Richards S. Advancements within Modern Machine Learning Methodology:
Impacts and Prospects in Biomarker Discovery. Curr Med Chem 2021;28:6512-6531.

54. Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, et al.
Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat
Biotechnol 2019;37:773-782.

Figure Legend

Figure 1. RNA sequencing data processing, integration, and analysis
A. Illustration of data processing.
B. Principal component analysis (PCA) based on the origin of datasets.
C. PCA based on normalized RNA abundance (nCount).
D. PCA based on NAS score.
E. PCA based on fibrosis scores.

Figure 2. Integrative transcriptome and proteomics analysis to identify NAFLD biomarkers
A. Heatmap presentation of 1021 up-regulated genes in cluster 4 associated with increasing NAS scores.
B. Heatmap presentation of 643 down-regulated genes in cluster 14 associated with increasing NAS scores.
C. Protein cluster of 148 up-regulated proteins associated with increasing NAFLD severity in PXD011839.
D. Protein cluster of 114 down-regulated proteins associated with increasing NAFLD severity in PXD011839.
E. (UP) Venn diagram showing 16 overlapping genes between up-regulated genes identified by RNA-seq, up-regulated proteins in the plasma, and secreting proteins. (DOWN) Venn diagram showing 22 overlapping genes between down-regulated genes identified by RNA-seq, down-regulated proteins in the plasma, and secreting proteins.

Figure 3. Relationship between QSOX1/IL1RAP and NAS/fibrosis scores in integrative RNA-seq data of the human liver.
A. Box plot of QSOX1 gene expressions grouped by NAS scores (N0, N1-4, N5-8).
B. Box plot of QSOX1 gene expressions grouped by fibrosis stages (F0, F1-2, F3-4).
C. Box plot of IL1RAP gene expressions grouped by NAS scores (N0, N1-4, N5-8).
D. Box plot of IL1RAP gene expressions grouped by fibrosis stages (F0, F1-2, F3-4).
E. Box plot of QSOX1/IL1RAP gene expression ratio grouped by NAS scores (N0, N1-4, N5-8).
F. Box plot of QSOX1/ IL1RAP gene expression ratio grouped by fibrosis stages (F0, F1-2, F3-4).
Statistical testing was performed using the Wilcoxon rank sum test, with p-values shown in the plot.

Figure 4. Comparison of plasma protein QSOX1/IL1RAP between healthy individuals and NAFLD at various stages.
A-B. Box plots of plasma QSOX1 (A) and IL1RAP (B) protein levels in healthy individuals, NAFLD patients, and cirrhosis patients quantified by mass spectrometry in the NAFLD proteomics cohort.

C. Box plots of plasma QSOX1 and IL1RAP protein ratios in healthy controls, NAFLD
patients, and cirrhosis patients quantified by mass spectrometry in the NAFLD
proteomics cohort.
D-E. Box plots of plasma QSOX1 (D) and IL1RAP (E) protein levels in healthy controls
and NAFLD groups (pg/ml) measured by ELISA.
F. Box plot of plasma QSOX1 and IL1RAP protein ratio.
Statistical testing was performed using the Wilcoxon rank sum test, with p-values
shown in the plot.
783
Figure 5. Quantification of liver QSOX1 and IL1RAP levels in NAFLD patients by IHC.
A. Representative IHC images of QSOX1 and IL1RAP in liver biopsies from mild NAFLD
patients (N0-4, F0-2) and severe NAFLD patients (N5-8, F3-4).
B. The integrated density of QSOX1 IHC. Box plots showing the log10 value.
C. The integrated density of IL1RAP IHC. Box plots showing the log10 value.
D. Box plot of QSOX1 and IL1RAP ratio of the integrated density quantified with IHC.
Statistical testing was performed using t-test, with p-values shown in the plot.
791
792 **Table 1**

Table 1: Characteristics of the populations studied							
A total of 625 human liver samples of the full histological range from normal, NAFL, NASH to cirrhosis with the NAS (N) and fibrosis (F) scores provided in the database or original articles.							
Sample distribution of NAS and FIB	F0	F1	F2	F3	F4	Age (yrs)	BMI (kg/m2)
						mean ± S.D.	mean ± S.D.
N0 (n)	81	1	1	-	1	46.4 ± 10.0	35.4 ± 9.1
N1 (n)	29	9	1	-	1	42.8 ± 12.7	36.1 ± 6.6
N2 (n)	27	10	1	-	1	51.9 ± 5.8	35.1 ± 6.0
N3 (n)	46	72	9	5	3	49.8 ± 9.4	34.6 ± 8.9
N4 (n)	30	19	20	15	3	49.6 ± 9.5	33.9 ± 4.6
N5 (n)	7	41	75	20	5	52.4 ± 11.7	32.5 ± 5.5
N6 (n)	1	18	17	18	3	53.2 ± 8.5	34.5 ± 5.6
N7 (n)	-	1	14	11	1	49.4 ± 9.8	36.3 ± 7.2
N8 (n)	-	-	2	4	2	54 ± 0.0	31.3± 0.0
Age (yrs) mean ± S.D.	46.6 ± 9.6	49.0 ± 10.6	53.2 ± 11.3	54.7 ± 6.0	54.8 ± 5.4		
BMI(kg/m2) mean ± S.D.	37.1± 8.3	32.4 ± 5.6	33.1 ± 7.0	32.5 ± 2.9	32.6 ± 2.2		
Gender n(male/female)	221(105/116)*	171 (108/63)*	140 (64/76)*	73 (35/38)*	20 (11/9)*		
Table 1. *The ratio of gender was estimated according to the gender ratio in the original articles. BMI, body mass index; N, NAS score; F, Fibrosis score.							

Figure 1

A

Raw RNA-seq data (N = 625 patients)

↓ RSEM

Gene Expression Transcript Per Million (TPM)

↓

Protein-coding genes expressed in all studies

↓ metaseqR

Trimmed Mean of M values per sample TMM

↓

Log 1p transform: log10(TMM+1)

↓ limma

Batch correction

↓

Expansion batch corrected log10(TMM+1) value

↓

Normalized gene expression

Figure 2

A Gene cluster 4 (n = 1021)

Z scores — low / high

LRCOL1, LAMC3, CDC42EP3, FSTL1, ALPK2, CNTN1, LYPD6B, VCAN, SHISA3, NQO1, ELF3, FABP4, FHL2, FMO2, GABBR1, PHF19, SULT1C4, GPX2, HOXB3, CXCL8, KRT19, LIMK2, MFGE8, NFATC1, COL5A3, PDE4A, PLAGL1, SLC35F2, BCAS4, SEMA3G, CRACD, WFDC1, S100A6, ROBO3, BMP4, STC1, TRPM2, DNALI1, MOB3B, PDGFD, CRISPLD2, TUBB6, KIAA1755, SPHK1, CHRDL1, ITM2A, GFPT2

N0 N1 N2 N3 N4 N5 N6 N7 N8

B Gene cluster 14 (n = 643)

Z scores — low / high

MAMLD1, FST, SMPDL3A, OSBPL6, ADH6, PLEKHA7, CMTM8, CYP27A1, FAM227B, F2, RHOBTB3, PHF8, MAFF, GCNT2, ANG, BLNK, HSD17B2, IL1RN, JUNB, SPDYC, MAF, ASS1, NAGA, PCK2, SCLY, CHRAC1, GID8, DHTKD1, KIAA1191, BCKDHB, POLR1E, WNK3, SRD5A1, TEF, CORO2A, CALM1, TMEM120A, PRSS12, NAT1, CPNE6, NR1I3

N0 N1 N2 N3 N4 N5 N6 N7 N8

C Protein up cluster

Z scores — low / high

A0A0X9T0H6, A0A193CHQ9, A2M, ACE, AHSG, B1N7B9, B3GNT2, BLMH, C1QA, C4A, CD14, CILP2, COL6A3, DKFZp686A03134, DKFZp686I04196, ECM1, F7, FBN1, FCGR3B, GPLD1, HEL107, HEL-S-130P, HEXA, HSPG2, IGFBP6, IGHV4-4, IGJ, IGLC7, KRT9, LCN2, LILRB3, MET, MRC1L1, P0DOX6, PIGR, PLTP, PVR, Q6GMW4, Q8N355, Q9UL90, RELN, SERPINA1, STMN1, TGFBI, TLN1, TRA1, V2-13, VH6DJ, VWF, XTP3TPATP1

Healthy / NAFLD / Cirrhosis

D Protein down cluster

Z scores — low / high

A0N7J6, AMY1A, ANXA1, APOB, APOM, C0IMJ3, C1QTNF3-AMACR, C3, C4BPA, C6, CAP1, CD99, CFHR3, CNTN3, DBH, DKFZp686G21125, DKFZp686O01196, EFEMP1, F5-20, FTL variant, GC, GOLPH2, HEL111, HEL-S-133P, HEL-S-153w, HEL-S-269, HEL-S-72p, HGFAC, HPR, HYOU1, IGFBP3, IGKV1-9, IL1RAP, ITIH2, KLKB1, LAR, LDHA, LILRA2, MAN1A1, MANBA, NAGLU, P4HB, PDIA3, PEPD, PLXNB2, PON3, PTPRF, PZP, RBP4, S100A8, SBSN, SERPINA10, SERPINF2, SMPDL3A, SPP2, ufHSD2, VCL

Healthy / NAFLD / Cirrhosis

E

UP

Transcript Cluster 4 / Secretome / Proteomics UP Cluster

769 — 233 — 1609 — [16] — 3 — 45 — 84

A2M, C7, COL6A3, COLEC11, ENPP2, FBLN1, FBN1, FCGBP, IGFBP6, LCN2, LUM, MMP2, PAPLN, PTGDS, **QSOX1**, VWF

DOWN

Secretome / Transcript Cluster 14 / Proteomics Down Cluster

1767 — 78 — [22] — 36 — 543 — 56

AZGP1, C1RL, C4BPA, C6, C8B, CFHR3, CNDP1, F2, GC, HP, HPR, **IL1RAP**, ITIH1, ITIH2, ITIH4, KLKB1, PON3, SERPINA10, SERPINC1, SERPING1, SMPDL3A, TTR

Figure 3

Figure 4

Figure 5